MedChem Australia is a first-of-its-kind national initiative providing and growing medicinal chemistry capability in Australia. We aim to help guide drug discovery projects towards clinical trials and, ultimately, create new therapies for a broad range of diseases.

We will help researchers and small companies overcome a critical capability barrier by providing medicinal chemistry & DMPK resources, plus expertise, at subsidised cost to aid project progression and enhance value.

Collaboration is central to our model and critical to our success. MedChem Australia will rely on the project provider for the biological rationale, starting chemical matter, expertise, and on-going project support and engagement.

Working together, we will aim to deliver an advanced and de-risked candidate or program with proof of concept data that is positioned for further investment.

MedChem Australia operates in the lead generation (hit to lead) and lead optimisation stages of Drug Discovery. We provide industry level medicinal chemistry + DMPK capabilities to advance drug discovery projects.

A true collaboration with an integrated project team and key contributions from all parties

MedChem Australia is a partnership between Monash University, WEHI, & the University of Sydney

MedChem Australia will comprise identical scale Nodes of activity at Monash, WEHI, and the University of Sydney.

Each Node contains state-of-the-art facilities for drug design and synthesis

DMPK profiling of compounds will be done at the Centre for Drug Candidate Optimisation (CDCO) at Monash

We acknowledge our funding partners